Skip to main content
Clinical Trials/NCT04808674
NCT04808674
Recruiting
N/A

EvalUation of REmediation Programs for Patients Suffering From Mild Cognitive Deficits After CAncer

Hospices Civils de Lyon2 sites in 1 country24 target enrollmentDecember 17, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cognitive Remediation
Sponsor
Hospices Civils de Lyon
Enrollment
24
Locations
2
Primary Endpoint
Self-reported cognitive function
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Cancer survival rates have improved significantly over the past decades and patients now experience a number of side effects including cancer-related cognitive impairment (CRCI): problems with memory, executive function, attention, and difficulties performing two tasks at the same time. The frequency of CRCI in cancer patients is estimated to be between 10 to 40%, and more than 50% of patients describe difficulties in their daily life. These cognitive difficulties negatively impact the patient's quality of life as well as that of their family, and can also have negative consequences for their social and professional reintegration once cancer treatment is finished. Despite an increasing number of studies on CRCI, a standard of care for patients with CRCI after breast cancer is yet to be established. In the absence of clear directives, and in an attempt to respond to the increasing demand to provide care for breast cancer patients with CRCI, physical medicine and rehabilitation units in France have started providing day-hospital multidisciplinary interventions. The objective of this project is to use the single case experimental design method to investigate the efficacy of two such rehabilitation programs: a group-based program and a one-on-one program.

Registry
clinicaltrials.gov
Start Date
December 17, 2021
End Date
July 17, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Treated in the past for breast cancer with chemotherapy, surgery, and / or radiotherapy,
  • Admitted as a day patient at the Henry Gabrielle Hospital or the Pontchaillou CHU Hospital during the study,
  • Given free, informed consent in writing after being informed orally and in writing of the how the study will proceed.

Exclusion Criteria

  • Presence of another active cancer,
  • Ongoing chemotherapy and/or radiotherapy treatment,
  • Active progression of breast cancer,
  • History of neurological or psychiatric conditions,
  • Major disturbances in comprehension that prevent them giving free, informed consent,
  • Pregnant, parturient or breastfeeding women,
  • Person under a legal protection measure such as guardianship or curatorship,
  • People not affiliated to a social security scheme (French Social Security) or beneficiaries of a similar scheme.

Outcomes

Primary Outcomes

Self-reported cognitive function

Time Frame: 16 weeks

The Fact-COG questionnaire assesses subjective cognitive impairment. The score directly reflects the patient's feelings about/perceptions of their cognitive function over the previous week. A total score out of 132 is obtained as well as 4 subscales: Perceived Cognitive Impairments (0-72), Impact on Quality of Life (0-16), Comments from Others (0-16), and Perceived Cognitive Abilities (0-28).

Secondary Outcomes

  • Fatigue(16 weeks)
  • Psychological distress(16 weeks)
  • Quality of Life with FACT-B questionnaire(16 weeks)
  • Neuropsychological function(16 weeks)

Study Sites (2)

Loading locations...

Similar Trials